Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8374 in Japanese patients with advanced solid tumors
NCT03945253Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2019
- Primary completion
- Jun 2020
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP8374 in solid tumor (advanced stage) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicity up to 21 days, Adverse Events up to 109 weeks and 4 more. Started Aug 2019; status: completed.
02
Drugs
ASP8374
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03945253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945253.